Kamie Zaracki, BetterInvesting, and Anthony Bonignore, University of South Carolina, share their stock picks ahead of a possible Fed rate hike.
CNBC's Jeff Cox spoke with billionaire investor Carl Icahn about his investment in Herbalife, and whether he feels trapped.
Billionaire investor Carl Icahn rejected any assertion Tuesday that he is backed into a corner on troubled nutritional supplement company Herbalife.
Stocks closed higher, with financials leading, as investors looked for clues about the Federal Reserve's next move.
CNBC Contributor Herb Greenberg discusses what's causing Herbalife's comeback today.
The “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Herbalife, as well as the company's release of new videos taking aim at Bill Ackman, Pershing Square Capital Management CEO.
CNBC’s Kate Kelly on the latest with billionaire Carl Icahn upping his stake in Herbalife by more than two million shares.
Mylan, Herbalife and T-Mobile are making headlines this Monday morning.
Some of the names on the move ahead of the open.
CNBC's Kate Kelly reports the latest on the Herbalife stock saga between Carl Icahn and Bill Ackman.
Matthew Handley alleged Herbalife made "purposefully deceptive statements" in its Aug. 3 quarterly earnings conference call and regulatory filings.
Sources tell CNBC Carl Icahn may have been interested in unloading his Herbalife stock earlier in August, but for the right price.
Herbalife shares slumped after Bill Ackman said he was approached to take a stake in the firm.
Carl Icahn bought 2.3 million shares of Herbalife and criticized Bill Ackman for obsessing over his short position in the company.
Carl Icahn slammed Pershing Square's Bill Ackman for making false statements about Icahn's Herbalife investment.
CNBC's Susan Li reports on a statement from Herbalife's CEO on Carl Icahn's purchase of 2.3 million more shares in the company.
CNBC's Susan Li reports that Carl Icahn has bought 2.3 million shares in Herbalife and released a statement in response to Pershing Square's Bill Ackman.
CNBC's Kate Kelly and CNBC Contributors Ron Insana and Herb Greenberg discuss the ongoing saga between Pershing Square's Bill Ackman and Carl Icahn over Herbalife.
CNBC's Scott Wapner, LOOP Capital President Kourtney Gibson and the "FMHR" traders discuss the latest on Herbalife, amid the dispute between Bill Ackman and Carl Icahn.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.